Search

Your search for "GNPX" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System

June 7, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the NRPL2 tumor suppressor gene. “The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Video Featuring Clinical Trial Patient Sharing Study Experience

June 2, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing therapies for patients with cancer and diabetes who have limited treatment options, has released a video featuring a patient from a recent clinical trial. The patient participated in the phase 1 portion of Genprex’s Acclaim-1 study. During the video, the patient shares her experience, […]

News Articles

Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment

June 2, 2023

Gene Therapy’s Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga. Click Here for the full article The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex’s innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives SRC Approval to Advance to Phase 2 Portion of REQORSA(R) Clinical Trial

May 30, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting results from the phase 1 portion of its Acclaim-1 phase 1/2 clinical trial. The trial is designed to evaluate Genprex’s proprietary REQORSA(R), used in combination with Tagrisso(R) (osimertinib) for the treatment of late-stage non-small […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Results of Phase 1 Clinical Trial Will Be Published at ASCO Meeting

May 26, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting on positive data gathered from the phase 1 portion of its Acclaim-1 clinical trial. The trial is designed to evaluate the company’s proprietary lead product candidate, REQORSA(R) Immunogene Therapy, in combination with Tagrisso(R) in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data with NPRL2 Gene Therapy

May 23, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video where the company’s Chief Medical Officer Mark Berger, MD discusses the recently presented positive preclinical data for the NPRL2 gene by Genprex’s research collaborators. The findings were presented at the 2023 […]

News Articles

Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting

May 17, 2023

Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments, announced last month that its research collaborators presented positive preclinical data for the NPRL2 gene, which is a tumor suppressor gene. The presentation was given at the 2023 American Association of […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate and Present at Upcoming May Industry and Investor Conferences

May 8, 2023

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced its participation in upcoming industry and investor conferences to be held in May 2023. These include the Sidoti Micro Cap Conference, the American Society of Gene & Cell Therapy Annual Meeting […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Data Supporting Therapeutic Potential of Its Non-Viral Delivery System

April 19, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for the NPRL2 gene (also known as the TUSC4 gene). According to the announcement, the studies used the company’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Research Findings, Additional Support for REQORSA(R) and Its Therapeutic Potential

April 18, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that unaffiliated, independent researchers recently presented preclinical data on the tumor suppressor gene, TUSC2, reporting that it functions as a novel tumor suppressor for glioblastoma. TUSC2 is the suppressor gene that is re-expressed in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Statement Regarding FDA Initiative to Accelerate Approval Process for Gene Therapies

March 23, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is commending the U.S. Food and Drug Administration (“FDA”) and the organization’s recent initiative, which is designed to expedite the development of gene therapies for patients with rare diseases. The government agency has announced that it […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Barcelona Conference

March 13, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its Chief Manufacturing and Technology Officer Hemant Kumar, Ph.D. will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023, in Barcelona, Spain. Dr. Kumar is scheduled to present at […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Management to Participate in Two Upcoming Conferences

March 8, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has announced its participation in two March conferences: the 35th annual Roth Conference and the BIO-Europe Spring Conference. The Roth Conference is scheduled for March 12–14, 2023, in Dana Point, California. During this conference, the company […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $4M Registered Direct Offering

February 27, 2023

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced its entry into a securities purchase agreement with a single, health care-focused institutional investor for the purchase and sale of 3,809,524 shares of its common stock together with warrants to purchase […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Inks Deal with University of Pittsburgh for Exclusive License to Diabetes Technology

January 5, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into an exclusive license agreement with the University of Pittsburgh. According to the announcement, the agreement gives Genprex a worldwide, exclusive license to a patent application along with related technology; the agreement also grants […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Gene Therapy Treatment Data to be Presented at Upcoming International Diabetes Conference

January 4, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that research evaluating the company’s gene therapy for type 1 diabetes will be presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (“ATTD”). The preclinical data will be presented by GNPX […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial, Licenses Additional Technology from University of Pittsburgh

December 15, 2022

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company has announced that the Safety Review Committee (“SRC”) approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA(R) in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Gene Therapies for Cancer and Diabetes at Upcoming Conference

December 2, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the upcoming RHK 2022 Disruptive Growth Conference taking place at the offices of Reed Smith in New York City on Dec. 5-6, 2022. Catherine Vaczy, Genprex’s EVP, general counsel […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Upcoming Investor, Industry Conferences

October 7, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has announced the lineup of conferences it will be attending in October. The company will also be participating in these events, with its corporate and clinical presentations highlighting GNPX gene therapies designed to treat cancer and […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CFO to Present Pioneering Gene Therapies at Upcoming Conference

September 8, 2022

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its Chief Financial Officer Ryan Confer will be providing a virtual overview of Genprex’s gene therapies for cancer and diabetes at the Wainwright 24th Annual Global Investment Conference. The event […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures New Patent, Critical Protection for REQORSA(TM) Combination Therapy

August 16, 2022

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that the United States Patent and Trademark Office (“USPTO”) has granted Genprex U.S. Patent No: 11,278,592 B2. According to the update, the patent covers methods of using REQORSA(TM) Immunogene Therapy in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial to Higher Dose

August 15, 2022

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that the Safety Review Committee (“SRC”) has approved continuation of the Acclaim-1 phase 1/2 clinical trial of REQORSA(TM) in combination with Tagrisso(R) (osimertinib) to treat late-stage non-small cell lung cancer (“NSCLC”) […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

July 13, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its manufacturing leadership will present sessions on cutting-edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit. The event is taking place from July 19-21, 2022, in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in June Investor Conferences

June 2, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be presenting at two upcoming investor conferences: the LD Micro Invitational and the BIO International Convention. The company’s participation will focus on its gene therapies for cancer and diabetes. Slated for June 7–9, 2022, the […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Investor Conference

May 19, 2022

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its CEO and President Rodney Varner will be providing a virtual overview of Genprex’s pioneering gene therapies to investors at the H.C. Wainwright Global Investment Conference. The event is slated […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CMO to Participate at 33rd Annual Cancer Progress Conference as Expert Panelist

May 9, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has announced that chief medical officer Mark Berger, MD, will be participating the upcoming Cancer Progress Conference. The conference, which will be held virtually, is slated for May 10–12, 2022. Berger has been invited to participate […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Shareholder Letter, 2022 Corporate Update

May 5, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has issued a shareholder letter and corporate update outlining the company’s recent progress in its clinical development programs and key milestones and achievements for 2022 and beyond. “We have had a strong […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in April 2022 Conferences

April 18, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, and management will be involved in two upcoming conferences. GNPX presenters will include chief financial officer Ryan Confer and chief medical officer Mark Berger. The conference presentations will spotlight the company’s gene therapies for cancer and […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Opens Acclaim-2 Clinical Trial for Patient Enrollment

March 31, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced the opening for patient enrollment of its Acclaim-2 clinical trial. According to the update, Acclaim-2 is an open-label, multi-center phase 1/2 clinical trial evaluating the company’s lead drug candidate, REQORSA(TM) Immunogene Therapy, in combination […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference

March 23, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its president and CEO Rodney Varner will provide an overview of the company’s gene therapies for cancer and diabetes at the 2022 BIO Europe Spring Investor Conference. The event is scheduled to take […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial

March 2, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the first patient was dosed in the Acclaim-1 clinical trial. The open-label, multi-center phase 1/2 clinical trial will evaluate the company’s lead drug candidate, REQORSA(TM) Immunogene Therapy, in combination with Tagrisso(R) (osimertinib) in […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate at February Investor Conferences

February 9, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating in two investor conferences this month. The company has announced that president and CEO Rodney Varner will be presenting to investors at both the 2022 BIO CEO and Investor Conference and at the […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Oncology Programs, Further Explore Use of ONCOPREX(R) Nanoparticle Delivery System

January 27, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators published positive preclinical data for the use of Genprex’s ONCOPREX(R) Nanoparticle Delivery System for delivery of a FAS DNA plasmid to treat metastatic colorectal cancer. The preclinical study, published in the […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Accelerate Opening of Acclaim-1 Clinical Trial Sites

January 10, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial. The trial combines the company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid) Immunogene Therapy with AstraZeneca’s Tagrisso(R) as a potential […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Upcoming Conferences

January 5, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating in two January conferences. The company announced that president and CEO Rodney Varner and chief medical officer Mark Berger, MD, will lead presentations in both the HC Wainwright 2022 Bioconnect Conference and the […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Oncology R&D Pipeline to Include Small Cell Lung Cancer

January 4, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has expanded its oncology research and development pipeline to include small cell lung cancer (“SCLC”) as an additional disease indication for its lead drug candidate, REQORSA(TM) Immunogene Therapy. SCLC represents approximately 10-15% […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted Fast Track Designation for Proprietary Immunogene Therapy from FDA

January 3, 2022

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it has received fast track designation (“FTD”) from the U.S. Food and Drug Administration (“FDA”) for its lead drug candidate: REQORSA(TM) Immunogene Therapy. The designation is for REQORSA in combination with Merck & Co’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present in CEO Roadshow Webinar

November 16, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the company’s president and chief executive officer Rodney Varner will be showcasing the company’s novel gene therapies in cancer and diabetes to investors via a webinar with CEO Roadshow. The CEO Roadshow webinar […]

News Articles

Genprex Inc. (NASDAQ: GNPX) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference

September 29, 2021

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop […]

InvestorNewsBreaks

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Strengthens Management Team with Strategic Appointments

September 28, 2021

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of chief medical officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).